{"entity":{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of CYH33 in ovarian cancer, run by Haihe Biopharma Co., Ltd., active and no longer recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma is a phase 2 interventional study registered as NCT05043922 by Haihe Biopharma Co., Ltd., with 93 participants enrolled, started 2021-10-11 and due to reach its primary completion in 2024-07-31. Interventions recorded: CYH33.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05043922","url":"https://clinicaltrials.gov/study/NCT05043922"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["haihe-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05043922","phase":"2","setting":"A Phase II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of CYH33, a Selective PI3Kα Inhibitor in Patients With Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell Carcinoma","sponsor":"Haihe Biopharma Co., Ltd.","enrolled":93,"outcomes":[]},"route":"/trials/nct05043922/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"}],"drug":[{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/"}]}}